30 results about "Ocular inflammation" patented technology

The invention relates to the technical field of pharmaceutical preparations, and provides double-shell JAK inhibitor nanoparticles, a preparation method thereof and targeted delivery eye drops. The double-shell JAK inhibitor nanoparticle provided by the invention comprises a core, an inner shell and an outer shell, wherein the core comprises a nanostructure lipid carrier and a JAK inhibitor; the inner shell layer is a cationic polymer, and the outer shell layer is hyaluronic acid. Through the design of the positive charge inner shell layer and the negative charge outer shell layer, the dual functions of mucosa adhesion and active targeting are achieved, the surface of the nanoparticle is electronegative finally, cytotoxicity possibly caused by direct exposure of a cationic polymer is reduced, non-specific aggregation of the cationic polymer and electronegative protein in tears is avoided, and the stability of tears is improved. And the stability of the preparation is improved. The eye drops provided by the invention can obviously prolong the residence time of the JAK inhibitor on the ocular surface, enhance the cornea permeability, can actively target to ocular inflammatory cells, and have a wide application prospect.

Provided herein are ophthalmic pharmaceutical compositions, including compositions containing a fixed dose combination of active agents that are suitable for topical delivery to the eye(s) of a subject. In embodiments, the ophthalmic pharmaceutical compositions contain a glucocorticoid receptor agonist and an intraocular pressure lowering agent. Also provided are methods of manufacturing ophthalmic pharmaceutical compositions of the disclosure. Further provided are methods involving coadministration of a glucocorticoid receptor agonist and an intraocular pressure lowering agent, such as in the treatment of a patient suffering from an ocular condition.

The invention relates to application of graphene-(RADA-IKVAV)-pranoprofen, eye drops and a preparation method of the eye drops. The invention relates to graphene-(RADA-IKVAV)-pranoprofen, the graphene-(RADA-IKVAV)-pranoprofen comprises graphene-polyacrylic acid, self-assembled oligopeptide RADA-IKVAV and pranoprofen, the self-assembled oligopeptide RADA-IKVAV is connected with the graphene-polyacrylic acid through a chemical bond, and the pranoprofen is loaded on the surface of the graphene-polyacrylic acid. The eye drops provided by the invention comprise graphene-(RADA-IKVAV)-pranoprofen, so that the drug loading capacity of pranoprofen in the eye drops is increased, the bioavailability of drugs is improved, and the eye drops are used for inhibiting eye inflammation; the coupled oligopeptide RADA-IKVAV simulates an extracellular environment, provides a suitable microenvironment for eyes, promotes nerve repair and regeneration by influencing nerve growth factors, and promotes optic nerve repair.

This invention provides a traditional Chinese medicine composition and its application in the preparation of a topical herbal eye patch for treating thyroid eye diseases, belonging to the field of biomedical technology. The herbal composition consists of *Gynostemma pentaphyllum*, peppermint, *Platycladus orientalis* leaves, borneol, cicada slough, *Astragalus membranaceus*, *Selaginella tamariscina*, *Pteris vittata*, *Scutellaria baicalensis*, apricot leaf, and *Ipomoea aquatica*. Using this herbal composition as raw material, a topical herbal eye patch is prepared. This patch acts directly on acupoints and skin around the eyes, allowing the medicinal properties to penetrate the skin and reach the eye system, achieving the effects of promoting blood circulation, clearing heat and detoxifying, invigorating qi and unblocking meridians, reducing swelling and improving vision. It is suitable for the treatment of thyroid-related eye diseases. This invention's topical herbal eye patch can effectively improve clinical symptoms such as exophthalmos and eye inflammation in patients with thyroid eye diseases, positively impacting their quality of life and effectively improving the clinical treatment efficacy of this disease. The topical herbal eye patch provided by this invention can be further promoted and applied in the clinical treatment of thyroid eye diseases.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.

Disclosed are methods, systems, media, apparatus, devices, and other implementations, including a method that includes determining blood flow characteristics at an ocular surface of an eye of a patient, determining characteristics of blood vessels at the ocular surface of the eye based on the determined blood flow characteristics, and deriving one or more ocular redness grading scales indicative of inflammation levels of the eye of the patient based on the determined characteristics of the blood vessels at the ocular surface of the eye.

The invention discloses eye health care liquid based on cortex berberidis and saffron crocus extracts and a preparation method of the eye health care liquid, and relates to the technical field of traditional Chinese medicine preparations and eye health care, in particular to the eye health care liquid based on the cortex berberidis and saffron crocus extracts and the preparation method of the eye health care liquid. According to the eye health-care liquid, a cortex berberidis extract and a saffron crocus extract are used as main active ingredients, a fructus lycii extract, a radix stemonae extract, a mint extract, a honeysuckle flower extract and other functional ingredients are used as auxiliary ingredients, and sodium hyaluronate, taurine and vitamin B6 are added to enhance the moisturizing, anti-oxidation and metabolic regulation effects. The preparation method comprises the steps of raw material extraction, extract concentration, auxiliary material mixing and pH adjustment, filtration and sterilization and the like. The product is suitable for eye atomization application, has the effects of relieving eye inflammation, improving microcirculation, relieving dryness, redness and swelling and the like, meanwhile strictly controls heavy metal and microbiological indexes, and guarantees use safety.

The present invention relates to ophthalmic compositions comprising at least one nicotinic acetylcholine receptor (nAChR) modulator, particularly varenicline, mecamillamine, and derivatives, and / or at least one substance of the endogenous Kennedy metabolic pathway, as well as salts and derivatives or pharmaceutically acceptable salts thereof, and choline-containing phospholipids, salts and derivatives thereof. Of these, choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (e.g., lecithin with a phosphatidylcholine content of 80% by weight or more, e.g., soy lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-α-glycerylphosphorylcholine, phosphatidylcholine, and phosphatidylethanolamine are particularly preferred.

The application discloses application of NSUN2 in treatment of wet age-related macular degeneration. The application research finds that inhibition or silencing of the NSUN2 gene can significantly inhibit ocular neovascularization, reduce ocular inflammatory response, and effectively inhibit the development of subretinal fibrosis, and the result shows that the NSUN2 can be used as a potential target for treating wet age-related macular degeneration. Therefore, the application provides a new strategy for treating wet age-related macular degeneration.

The present application relates to a kind of eye drops for treating dry eye and its preparation method, eye drops include by mass percentage: 0.05-0.5% of the extract of Monarda, 0.1-0.4% of silk fibroin nanoparticles coated with lutein, 0.1%-0.5% of chondroitin sulfate, 0.9-1.0% of sodium chloride, 0.05%-0.1% of poloxamer, 0.01%-0.1% of EDTA, phosphate buffer and water;The particle size of silk fibroin nanoparticles coated with lutein is 50-300nm, water is pharmaceutical sterile water, and the pH of eye drops is adjusted to 7.0-7.8 by phosphate buffer solution.The eye drops of the present application can effectively relieve dry eye symptoms, provide long-term wetting and protection, while reducing ocular inflammation and oxidative stress, can promote the repair of corneal injury, and effectively reduce the expression level of inflammatory factors, and high use safety.

Methods and pharmaceutical compositions for treating ocular disease are disclosed, including ocular disease involving ocular vascular permeability or ocular inflammation. In various aspects and embodiments, the invention comprises administering about 1 μg to about 1 mg of collagen IV-derived biomimetic peptide or salt thereof to a patient by intraocular injection. Injections are provided at a frequency of from about monthly to about once every two years. In various embodiments, the methods and compositions provide for potent action and long duration of action, with infrequent intravitreal injections of a small volume.

The present invention relates to use of a recombinant type III humanized collagen and a composition comprising the same in an eye. Provided are use of a recombinant type III humanized collagen in the preparation of a product for preventing and / or treating eye inflammation, a composition comprising the recombinant type III humanized collagen, and use of the composition in the preparation of a product for preventing and / or treating eye inflammation and / or eye dryness. The recombinant type III humanized collagen and the composition comprising the same can significantly promote the renewal and repair of corneal epithelial cells, and can also inhibit the release of inflammatory mediators, enhancing the ocular tissue barrier, enhancing tear film stability, and alleviating eye inflammation and eye dryness.

The application discloses a synthesis method and application of a cyclic hexapeptide scleramide, and the structure of the cyclic hexapeptide scleramide is as follows: the cyclic hexapeptide scleramide is coupled with FMOC-Gln(trt)-N-Me-Phe, FMOC-glycine, FMOC-N-methyl-L-phenylalanine and FMOC-L-phenylalanine in the order from the C terminal to the N terminal of the cyclic peptide sequence of the cyclic hexapeptide scleramide in the presence of a condensation reagent and an organic base by using glycine-resin, and then the protecting group is removed by using an organic base, so that the amino acid sequence, the cyclization mode and the modification site can be accurately controlled through solid-phase / liquid-phase synthesis technology, the efficient preparation of the cyclic hexapeptide scleramide compound is realized, and the limitation of a natural source is broken; meanwhile, the compound has significant anti-inflammatory activity, and provides an alternative compound for developing a new eye inflammation drug.

Dendrimer compositions and methods for treating one or more ocular inflammatory and / or angiogenic diseases and / or conditions, including hydroxyl-terminated dendrimers complexed or conjugated to one or more active agents for treating or reducing one or more symptoms of an ocular disease, and / or for diagnosing an ocular disease and / or condition. The dendrimers can include one or more ethylenediamine core poly(amidoamine) (PAMAM) hydroxyl-terminated generation 4, 5, 6, 7, 8, 9, or 10 dendrimers. The active agent can be a VEGFR tyrosine kinase inhibitor, including sunitinib or an analog thereof. Preferably, the compositions are suitable for administration via a systemic route to target activated microglia / macrophages in the retina / choroid.

The present disclosure relates to peptide compositions and methods for treating an inflammatory condition such as ocular inflammation, retinal inflammation, dry eye, uveitis, allergic conjunctivitis, and inflammation resulting from nerve injury or nerve degeneration. The peptide compositions disclosed herein can also be used for treating pain such as neuropathic pain, ocular pain, chronic pain, pain resulting from chemotherapy or radiation, pain resulting from nerve injury or nerve degeneration, and pain resulting from an inflammatory condition, dysesthesia, or allodynia.

The application provides a kind of nano preparation with antioxidant function and the use for treating glaucoma, the preparation is composed of oil phase and water phase.Oil phase is lecithin, medium-chain triglyceride, fat-soluble antioxidant, glaucoma treatment drug, water phase is water-soluble antioxidant or deionized water.The nano delivery system described in the application is by loading glaucoma treatment drug in the nano preparation containing antioxidant, can improve local drug concentration, prolong drug retention time, at the same time, through antioxidant scavenging excess active oxygen, reduce inflammatory response, reduce eye cell apoptosis, so as to achieve good therapeutic effect.The nano preparation described in the application can be nano emulsion, liposome, micelle or lipid nanoparticle and other drug delivery systems.The nano preparation can deliver therapeutic drugs while scavenging ROS, reducing eye inflammation and reducing cell apoptosis to achieve more efficient therapeutic effect, with the characteristics of double effect, easy to produce and prepare, wide application range, etc.

The present invention relates to a composition for preventing or treating ocular diseases, comprising Aloe vera gel. Specifically, when orally administered, the Aloe vera (A.vera) gel has been confirmed to have an excellent effect of increasing the expression of genes related to the improvement of tear volume, corneal non-uniformity, eye inflammation, dry eye, corneal thickness, and tear film. Accordingly, the Aloe vera gel can be advantageously used as an active ingredient in an oral composition for the prevention, alleviation, or treatment of ocular diseases, including dry eye syndrome.

The invention provides an aqueous liquid composition for ophthalmic administration, comprising therapeutically effective amounts of a ketorolac compound and of a corticosteroid, wherein the ketorolac compound is present in an essentially dissolved form; wherein the corticosteroid is present in the form of suspended particles; and wherein the composition exhibits an acidic pH of about 6.5 or less. The invention further provides compositions as disclosed herein for use in the prevention or treatment of ocular inflammation and methods for preventing or treating ocular inflammation in a subject.

Disclosed are a reactive aldehyde species (RASP) inhibitor designed on the basis of AI, and a use thereof. The RASP inhibitor comprises a compound represented by general formula (I) or a derivative thereof, wherein R1 and R2 are each independently selected from any one of hydrogen, a C2-6 unsaturated hydrocarbon group, a C1-6 alkoxy group, a C2-6 haloalkyl group, halogen, an amino group, a C3-20 cycloalkyl group, or a heterocyclic group containing 4-20 ring atoms; X is carbon or nitrogen; the derivative comprises at least one of a fluorescent label, a spin label, a heavy metal label, an isotope label, and a pharmaceutically acceptable salt. The provided RASP inhibitor has excellent capability and speed in sequestering aldehydes, and when applied to a lesion site, can quickly and effectively sequester RASP, to reduce the RASP level at the lesion site, thereby diminishing or preventing ocular inflammation. The RASP inhibitor shows potential preventive or therapeutic effects in various ocular inflammatory diseases such as dry eye disease.

Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for treating ocular diseases or conditions, including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. The compositions and methods comprise steroids and prostaglandins that exhibit anti-inflammatory activity, reduce intraocular pressure (IOP), and / or other desirable activities. Injection of the compositions in the eye provides therapeutic benefits to patients suffering from ocular conditions.

This disclosure features clusterin (CLU) as a multifunctional biotherapeutic for promoting ocular nerve regeneration for various ocular conditions. This disclosure features methods of using CLU for treating a subject with an ocular disorder, condition, or disease (e.g., an ocular surface disease, corneal disease or retinal disease). The methods described herein can be used for the treatment of ocular inflammatory conditions involving barrier disruption and nerve loss due to its ability to protect and promote the regeneration of ocular nerves.

The invention discloses gel eye drops containing bromfenac sodium and moxifloxacin hydrochloride as well as a preparation method and application of the gel eye drops, and belongs to the technical field of medicines. Comprising the following raw materials in parts by weight: 0.8-1.2 parts of bromfenac sodium, 0.8-6 parts of moxifloxacin hydrochloride, 15-30 parts of a gel matrix, 3-15 parts of sodium hyaluronate, 8-12 parts of an osmotic pressure regulator, 7.0-9.0 parts of citric acid, 0.02-0.05 part of sodium citrate and 950-1050 parts of purified water. The bromfenac sodium and the moxifloxacin hydrochloride are compounded, and the gel matrix, the sodium hyaluronate, the osmotic pressure regulator, the citric acid, the sodium citrate and the purified water are matched, so that the compound gel eye drops which are free of preservatives, low in irritation, good in stability, capable of improving the bioavailability of drugs and capable of achieving anti-inflammatory and antibacterial synergistic interaction are achieved, and eye inflammation can be effectively treated.

The application discloses a traditional Chinese medicine microemulsion eye drop as well as a preparation method and application thereof, and comprises the following components in percentage by weight: 0.001% to 2.0% of baicalein, 0.001% to 2.0% of borneol, 0.1% to 20% of oil for injection, 0.1% to 10% of a surfactant, 0.1% to 10% of a phospholipid, 0.1% to 5% of an osmotic pressure regulator, and the balance of water. The baicalein and borneol are combined to prepare an oil-in-water emulsion containing borneol and baicalein, so that the mutual synergistic effect is achieved, the opportunity of the medicine entering the cornea and the inflammatory site of the eye is increased, the medicine is rapidly introduced into the eye tissue, the curative effect is enhanced, the in-eye retention time is obviously prolonged, the corneal permeability of the medicine is increased, the non-invasive drug administration mode treatment for AMD patients and the treatment for various types of eye fatigue are realized.

The invention discloses an active aldehyde substance inhibitor based on AI design and application thereof. The active aldehyde substance inhibitor comprises a compound shown in a general formula (I) or a derivative thereof, and in the general formula (I), R1 and R2 are independently selected from any one of hydrogen, C2-6 unsaturated alkyl, C1-6 alkoxy, C2-6 halogenated alkyl, halogen, amino, C3-20 cycloalkyl or heterocyclic radical with 4-20 ring atoms; x is carbon or nitrogen; the derivative comprises at least one of a fluorescent marker, a spin marker, a heavy metal marker, an isotope marker and pharmaceutically acceptable salt. The active aldehyde substance (RASP) inhibitor provided by the invention has better capability and speed of complexing aldehyde, and can be quickly and effectively complexed with the active aldehyde substance after being applied to a diseased region, so that the content of RASP in the diseased region is reduced, and further, eye inflammation is reduced or avoided; the eye drops have potential prevention or treatment effects on various eye inflammatory diseases such as xerophthalmia and the like.

The invention consists of forceps with rounded gripping tips. These rounded tips are designed to prevent perforation of the amniotic membrane during its insertion onto the ocular surface for the treatment of dry eye and ocular inflammation, as well as to prevent injury to the conjunctiva during its removal. The forceps have gripping tips at their distal end, one of which has a notch on its inner surface. The dimensions of the notch allow the ophthalmologist to securely grasp the edge of the amniotic membrane to facilitate its insertion and removal from the ocular surface.

The present invention relates to isocyclosporin A, salts and ophthalmic compositions thereof for ophthalmic topical use in the prevention or treatment in an individual of an ophthalmic inflammatory and / or autoimmune disease, preferably selected from corneal and ocular surface inflammatory and / or autoimmune diseases and eyelid margin inflammatory diseases.

The application discloses application of SELE in treatment of wet age-related macular degeneration. The application research finds that SELE can significantly promote proliferation, migration and tube formation ability of vascular endothelial cells. SELE By inhibiting gene expression or activity, the application can significantly inhibit choroidal neovascularization in a wAMD mouse model, reduce abnormal vascular leakage, effectively reduce ocular inflammatory response, reduce inflammation-mediated vascular damage, target intervention of biological behavior of vascular endothelial cells, and block a key link of pathological angiogenesis. The application provides a novel molecular target for wAMD treatment and breaks the limitation of the existing anti-VEGF therapy.

The invention discloses an application of SELE in treatment of wet age-related macular degeneration. The research finds that the SELE can obviously promote the proliferation, migration and tube forming ability of vascular endothelial cells. By inhibiting SELE gene expression or activity, choroidal neovascularization in a wAMD mouse model can be significantly inhibited, and abnormal vascular leakage is reduced; meanwhile, the eye inflammatory response is effectively reduced, the inflammation-mediated vascular injury is relieved, the vascular endothelial cell biological behavior is intervened in a targeted manner, and the key link of pathological angiogenesis is blocked. The invention provides a brand new molecular target for wAMD treatment, and breaks through the limitation of the existing anti-VEGF therapy.

The present disclosure relates to among other things, an ophthalmic formulation of a lipidated chemerin composition comprising (a) chemerin or a fragment or analog thereof and (b) a lipid entity linked to the chemerin or fragment or analog thereof, that is stable in terms of pH, osmolality, physical appearance, and purity of the chemerin composition, when stored under normal storage conditions. One aspect of the present disclosure also relates to use of the said ophthalmic formulation for treating an inflammatory condition including, but not limited to, ocular inflammation, dry eye disease, and ocular neuropathic pain.

The present invention relates to isocyclosporin A, salts and ophthalmic compositions thereof for ophthalmic topical use in the prevention or treatment in an individual of an ophthalmic inflammatory and / or autoimmune disease, preferably selected from corneal and ocular surface inflammatory and / or autoimmune diseases and eyelid margin inflammatory diseases.